Cargando…

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors

Rationale: PD1/PD-L1 immune checkpoint inhibitors have shown promising results for several malignancies. However, PD1/PD-L1 signaling and its therapeutic significance remains largely unknown in intrahepatic cholangiocarcinoma (ICC) cases with complex etiology. Methods: We investigated the expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jia-Cheng, Zeng, Hai-Ying, Sun, Qi-Man, Meng, Qing-Nan, Huang, Xiao-Yong, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Wei, Chuan-Yuan, Shen, Ying-Hao, Cai, Jia-Bing, Dong, Rui-Zhao, Shi, Ying-Hong, Sun, Hui-Chuan, Shi, Yujiang G., Zhou, Jian, Fan, Jia, Ke, Ai-Wu, Yang, Liu-Xiao, Shi, Guo-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643449/ https://www.ncbi.nlm.nih.gov/pubmed/31367249 http://dx.doi.org/10.7150/thno.36276

Ejemplares similares

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
por: Gao, Zheng, et al.
Publicado: (2022)

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion
por: Meng, Xian-Long, et al.
Publicado: (2022)

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
por: Fontugne, Jacqueline, et al.
Publicado: (2017)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
por: Zhang, Jun, et al.
Publicado: (2020)

Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis
por: Huang, Xiao-Yong, et al.
Publicado: (2020)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
por: Lu, Jia-Cheng, et al.
Publicado: (2021)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma
por: Xie, Nan, et al.
Publicado: (2017)

Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma
por: Zhang, Chi, et al.
Publicado: (2013)

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients
por: Deng, Min, et al.
Publicado: (2021)

Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
por: Zhu, Shu-Guang, et al.
Publicado: (2022)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

PD‐L1/PD‐L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK
por: Cao, Yihui, et al.
Publicado: (2022)

A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma
por: Zheng, Bo-Hao, et al.
Publicado: (2017)

Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients
por: Huang, Xiao-Yong, et al.
Publicado: (2014)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
por: Yang, Hui, et al.
Publicado: (2022)

Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies
por: Cai, Hao, et al.
Publicado: (2015)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Yang, Jie, et al.
Publicado: (2020)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
por: Ma, Li-Jie, et al.
Publicado: (2018)

Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Jeong, Seogsong, et al.
Publicado: (2016)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Overexpression of UHRF2 in intrahepatic cholangiocarcinoma and its clinical significance
por: Peng, Rui, et al.
Publicado: (2017)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice
por: Wabitsch, Simon, et al.
Publicado: (2021)

Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients
por: Tao, Ping, et al.
Publicado: (2020)

Overexpression of PD‐L1 causes germ cells to slough from mouse seminiferous tubules via the PD‐L1/PD‐L1 interaction
por: Fang, Lian, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018)

Proteome Landscapes of Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Yi, Xiao, et al.
Publicado: (2023)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target
por: Gao, Qiang, et al.
Publicado: (2014)

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
por: Wang, Zhihong, et al.
Publicado: (2021)

Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel
por: Li, Xiaocheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kogvvuv289ief2g7kag7jckbc3